V InterAmerican Oncology Conference: 'Current Status and Future of Anti-Cancer Targeted Therapies'
- Start Date:
- Thursday, 10 October, 2013
- End Date:
- Friday, 11 October, 2013 7:00pm
- Oncology, Hematology
V InterAmerican Oncology Conference'Current Status and Future of Anti-Cancer Targeted Therapies' Universidad Católica ArgentinaOctober 10-11, 2013 Buenos Aires, Argentina First Announcement The Fifth Conference of IAOC "Current Status and Future of Anti-Cancer Targeted Therapies" will be held in Buenos Aires, Argentina in October 10th and 11th, 2013.An outstanding faculty of speakers from the United States and Europe has committed in this meeting.
The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types. The meeting objectives are designed to introduce the audience to the latest information on targeted therapies, immunotherapies and emerging treatments in early development. The major emphasis will be on clinical aspects of cancer treatment in the 21st century with discussion of significant scientific advances underlying the novel approaches still in preclinical development.This meeting is the primary opportunity for oncologists and cancer related health workers to participate in a conference focusing on novel targeted therapies and other treatment advances which are changing the face of cancer care.
Co- Chairs Román Perez Soler, New York, USACarlos L. Arteaga, Nashville, USA Organizing CommitteeRomán Pérez Soler, New York, USA.Carlos L. Arteaga, Nashville, USA.Andrea Blanco, Buenos Aires, Argentina. Scientific Committee Alex Adjei, M.D., Ph.D., Roswell Park Cancer Institute, Buffalo, New York, USA Kenneth C. Anderson, M.D., Dana-Farber Cancer Institute Boston, Massachusetts, USACarlos L.
Arteaga, M.D., Vanderbilt University School of Medicine, Nashville, USAHernán Cortes Funes, M.D., Hospital Universitario "12 de Octubre", Madrid, SpainRoman Perez Soler, M.D., Albert Einstein College of Medicine, Bronx, New York, USAJosep Tabernero, M.D., Vall d'Hebron University Hospital, Barcelona, Spain Faculty (provisionary) Alex A. Adjei, M.D., Ph.D. Professor and Chair, Department of Medicine Katherine Anne Gioia Chair in Cancer Medicine Roswell Park Cancer InstituteBuffalo, New York, USA Kenneth C.
Anderson, M.D. Kraft Family Professor of MedicineHarvard Medical SchoolDana-Farber Cancer InstituteBoston, Massachusetts, USA Carlos L. Arteaga, M.D.Professor of Medicine and Cancer BiologyAssociate Director for Clinical ResearchDirector, Breast Cancer ProgramVanderbilt - Ingram Cancer CenterNashville, Tennessee, USA Joaquim Bellmunt M.D., Ph.D.NAQAA Professor of MedicinePompeu Fabra UniversitySection Chief, Solid Tumor Oncology (GU & GI) Medical Oncology Service, Hospital del Mar Barcelona, Spain Robert L.
Coleman, M.D.Professor & Vice Chair, Clinical ResearchDepartment of Gynecologic Oncology& Reproductive MedicineUniversity of Texas, M.D. Anderson Cancer CenterHouston, Texas, USA Jorge Cortes, M.D. Professor of MedicineChief, CML & AML SectionsDeputy Chair, Department of LeukemiaMD Anderson Cancer CenterHouston, Texas, USA Hernán Cortés Funes, M.D.Department of Medical Oncology Hospital Universitario "12 de Octubre" Madrid, Spain John P.
Leonard, M.D.Richard T. Silver Distinguished Professor of Hematology and Medical OncologyAssociate Dean for Clinical ResearchChief, Lymphoma Service,Vice Chairman for Clinical ResearchWeill Cornell Cancer CenterNew York, New York, USA Román Pérez-Soler, M.D. Chairman, Department of OncologyMontefiore Medical Center Albert Einstein College of Medicine Bronx, New York, USA Daniel P. Petrylak, M.D.Director, Genitourinary Oncology ProgramCo Director, Signal Transduction ProgramYale University Cancer CenterNew Haven, Connecticut, USA Jeffrey A.
Sosman M.D. Professor of Medicine Ingram Professor for Cancer Research Vanderbilt University Medical Center Division of Hematology/Oncology Nashville, Tennessee, USA Josep Tabernero, M.D. Chairman Medical Oncology Department Vall d'Hebron University Hospital Barcelona, Spain Vicente Valero, M.D.,F.A.C.P.Professor of Medicine, Deputy ChairmanDepartment of Breast Medical OncologyUniversity of Texas M.D. Anderson Cancer CenterHouston, Texas, USA John J.
Wright, M.D., Ph.D. Associate Branch ChiefInvestigational Drug BranchNational Cancer Institute Bethesda, Maryland, USA PRELIMINARY PROGRAM NEW ANTICANCER THERAPIES Promising Novel Agents in Early Clinical Trials:Alex A. Adjei,Buffalo, USA New Drug Development at the NCI:John J. Wright, Bethesda, USA Use of Molecular Markers to Select Patients:Román Pérez Soler, New York, USA PI3K/TOR Pathway Inhibitors:Carlos L.
Arteaga, Nashville, USA Targeted Therapy for Melanoma:Jeffrey A. Sosman, Nashville, USA WOMEN´S CANCER · New Drugs in Breast Cancer:Vicente Valero, Houston, USA Current and Future Treatments in Breast Cancer:Hernán Cortés Fúnes, Madrid, Spain Hormonal Therapies and Combinations to Bypass Resistance:Carlos L. Arteaga, Nashville, USA New Therapies in Ovarian Cancer: Robert L. Coleman, Houston, USA GU AND GI CANCER New Targeted Therapies in Prostate and Renal Cancer:Daniel P.
Petrylak, New Haven, USA Advances in the Management of Metastatic Urothelial Cancer:Joaquim Bellmunt, Barcelona, Spain Treatment for Advanced Colorectal Cancer:Josep Tabernero, Barcelona, Spain LUNG CANCER New Targets in Lung Cancer:Alex A. Adjei, New York, USA Advances in Frontline Treatment:Román Pérez Soler, New York, USA HEMATOLOGICAL MALIGNANCIES New Developments in Lymphoma: John P. Leonard, New York, USA Multiple Myeloma: Kenneth C. Anderson, Boston, USA Leukemia: Jorge Cortes, Houston, USA
Alicia Moreau de Justo 1680,
Conference organized by InterAmerican Oncology Conferences